Ethinylestradiol / Gestodene: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
SMC (Scotland) recommended or restricted ethinylestradiol / gestodene, while AWMSG (Wales) did not recommend it.
HAS (France) has been harder on ethinylestradiol / gestodene than on its own caseload: it refused 7 of 15 decisive submissions here (47%), against a base rate of 11% across everything it has assessed.
The record spans 4.5 years, opening at HAS (France) on 31 Mar 2010 and running to 24 Sep 2014.
HAS (France) changed its position: recommended on 31 Mar 2010, not recommended by 19 Sep 2012.
Coverage is thin among the largest agencies: 5 of the eight highest-volume bodies — PBAC (Australia), PHARMAC (New Zealand) and TLV (Sweden) among them — hold no record for ethinylestradiol / gestodene at all.
Nothing has been added since 2014; on this evidence the file is dormant.
Against its own class, ethinylestradiol / gestodene is an outlier: 53% of its decisive outcomes were positive, where molecules sharing ATC class G03C average 81%.
3 distinct indication wordings are recorded for ethinylestradiol / gestodene by the agencies that label one in English (AWMSG and SMC).
HAS (France) was first to assess ethinylestradiol / gestodene, on 31 Mar 2010; AWMSG (Wales) did not open a file until 13 Apr 2011 — a moderate spread of 1.1 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 4 years in total.
2 of the 3 agencies here assessed ethinylestradiol / gestodene more than once, HAS (France) most often at 15 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 3 of the 18 agencies here have assessed ethinylestradiol / gestodene.
The full ledger for ethinylestradiol / gestodene reads 9 recommended, 8 not recommended and 1 not assessed.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AWMSG (Wales) | 24 Sep 2014 | Female hormonal contraception | not endorsed (non-submission) | source |
| HAS (France) | 19 Sep 2012 | Re-assessment of SMR | SMR insufficient | source |
| HAS (France) | 19 Sep 2012 | Re-assessment of SMR | SMR insufficient | source |
| HAS (France) | 2 Nov 2011 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| SMC (Scotland) | 11 Oct 2010 | Oral contraceptive | accepted | source |
13 further decisions for ethinylestradiol / gestodene, across 2 agencies, are not shown here. They link to 9 further source documents.
Related molecules
- ethinylestradiol / levonorgestrel — same ATC class G03C — Sex hormones and modulators
- estriol — same ATC class G03C — Sex hormones and modulators
- estradiol — same ATC class G03C — Sex hormones and modulators
- estradiol / norethisterone / relugolix — same ATC class G03C — Sex hormones and modulators
- apixaban — also decided by AWMSG in 2014Q3
- imatinib — also decided by AWMSG in 2014Q3
Coverage: 18 decisions for ethinylestradiol / gestodene from 3 agencies, 2010 to 2014. Data to 7 Sep 2026. ATC class G03C — Sex hormones and modulators. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.